AVTR — Avantor Inc. stock price and chart

AVTR

$15.65+0.38%

as of close, Nov 4, 2026

☾ AH $15.65 +0.38%

Avantor Inc.Stock · HealthcareRussell 1000 · 0.009% of IWBUS Stock Market · 0.009% of VTIRussell 3000 · 0.009% of IWV

PeersBAXELANRGENALGNINCYGEHC

Share this page

Head-to-head:Compare with BAX or any ticker →

Technical analysis2

Overlay lines0

Addendum charts0

Available history since May 22, 2019

VolumeEEEEEEEEEEEEEEEEEEEEEE

20192021202320242026

10.015.020.025.030.035.040.00100.0M$15.65

2026-11-04

Price$15.65

MA20$14.81

MA50$11.33

Vol18.7M

What would $1,000 invested in AVTR be worth today? →

AVTR returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $15.65
YTD price return: +36.56%
YTD total return: +36.56%
Market cap: 10.6B2019-06 2.5B2026-11 10.6B+318.3% over the window
Enterprise value: 14B
Shares outstanding: 677.6M2018-09 132.8M2026-09 677.6M+410.3% over the window
52W low: $7.27
52W high: $17.45
From 52W high: -10.32%
From 52W low: +115.42%
52W range: 82%$7.27–$17.45

Volume

Rel volume: 1.00×
30D volume: 9.9M
30D $ vol: 159.6M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3MNo open-market insider purchase or sale with a transaction date in the last 91 days, as filed on Form 4.: none
Insider net 1Y5 insider-days of buying ($2.7M) and 0 of selling (no priced lot) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: +$2.7M

Form 4 transactions by trade date, as filed; latest on file 2026-05-08.

Fundamentals

Sales (ttm): 6.6B2017-12 1.2B2026-09 6.6B+432.0% over the window
Sales/share: $9.792018-12 $44.162026-09 $9.79-77.8% over the window
EPS (ttm): $0.502018-12 -$2.692026-09 $0.50-118.5% over the window
FCF (ttm): 439.2M2017-12 -192.7M2026-09 439.2M-327.9% over the window
FCF/share: $0.652018-12 $1.232026-09 $0.65-47.1% over the window
Book value/share: $8.612018-03 -$20.242026-09 $8.61-142.6% over the window
Net margin: 5.08%2017-12 -9.0%2026-09 5.1%-156.2% over the window
ROE: 5.78%2019-06 -3.1%2026-09 5.8%-289.0% over the window
ROA: 2.90%2018-12 -0.9%2026-09 2.9%-430.7% over the window
Debt / equity: 0.63×2019-06 2.132026-09 0.63-70.6% over the window
Current ratio: 1.892018-12 1.732026-09 1.89+9.3% over the window

Growth (CAGR, ttm) · 10Y

Sales: +0.92%2025-09-30 → 2026-09-306.6B → 6.6B (+0.9% total)-1.95%2023-09-30 → 2026-09-307B → 6.6B (-5.7% total)-1.81%2021-09-30 → 2026-09-307.3B → 6.6B (-8.7% total)n/a
Net income: n/a-2.54%2023-09-30 → 2026-09-30364.3M → 337.2M (-7.4% total)-8.66%2021-09-30 → 2026-09-30530.2M → 337.2M (-36.4% total)n/a
FCF: -16.13%2025-09-30 → 2026-09-30523.6M → 439.2M (-16.1% total)-14.17%2023-09-30 → 2026-09-30694.6M → 439.2M (-36.8% total)-12.72%2021-09-30 → 2026-09-30867.3M → 439.2M (-49.4% total)n/a
Shares: -0.62%2025-09-30 → 2026-09-30681.8M → 677.6M (-0.6% total)+0.06%2023-09-30 → 2026-09-30676.4M → 677.6M (+0.2% total)+2.14%2021-09-30 → 2026-09-30609.5M → 677.6M (+11.2% total)n/a

Per-share growth (CAGR, ttm) · 10Y

EPS: n/a-2.60%2023-09-30 → 2026-09-30$0.54 → $0.50 (-7.6% total)-8.85%2021-09-30 → 2026-09-30$0.79 → $0.50 (-37.1% total)n/a
Sales/share: +1.55%2025-09-30 → 2026-09-30$9.64 → $9.79 (+1.5% total)-2.01%2023-09-30 → 2026-09-30$10.41 → $9.79 (-5.9% total)-3.87%2021-09-30 → 2026-09-30$11.93 → $9.79 (-17.9% total)n/a
FCF/share: -15.61%2025-09-30 → 2026-09-30$0.77 → $0.65 (-15.6% total)-14.22%2023-09-30 → 2026-09-30$1.03 → $0.65 (-36.9% total)-14.56%2021-09-30 → 2026-09-30$1.42 → $0.65 (-54.5% total)n/a
Book value/share: +5.42%2025-09-30 → 2026-09-30$8.17 → $8.61 (+5.4% total)+4.54%2023-09-30 → 2026-09-30$7.54 → $8.61 (+14.2% total)+5.04%2021-09-30 → 2026-09-30$6.74 → $8.61 (+27.9% total)n/a
Price: +35.17%2025-11-04 → 2026-11-04$11.58 → $15.65 (+35.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.20%2023-11-03 → 2026-11-04$18.37 → $15.65 (-14.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-16.65%2021-11-04 → 2026-11-04$38.91 → $15.65 (-59.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +35.17%2025-11-04 → 2026-11-04$11.58 → $15.65 (+35.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.20%2023-11-03 → 2026-11-04$18.37 → $15.65 (-14.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-16.65%2021-11-04 → 2026-11-04$38.91 → $15.65 (-59.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 31.5×2019-06 -48.852026-11 31.45-164.4% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 21.8×2019-06 5.472026-11 21.77+298.0% over the window
Fwd P/E: 17.7×
P/S (ttm)Market cap ÷ TTM revenue.: 1.6×2019-06 0.432026-11 1.60+273.6% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 1.8×2019-06 -0.812026-11 1.82-325.0% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 24.1×2019-09 28.772026-11 24.15-16.1% over the window
EV/EBITDA (fy): 15.5×
EV/Sales (ttm): 2.1×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.14%2019-06 8.1%2026-09 4.3%-47.1% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-09-30) ÷ shares_at(2025-09-30) = 1 − 677.6M ÷ 681.8M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 0.62%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (0.62%) + dividends paid over that year ($0) ÷ market_cap_at(2025-09-30) ($8.5B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 0.62%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($75.1M) ÷ today's market cap ($10.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.71%2019-06 0.0%2026-09 0.7%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $75.1M + TTM dividends $0) ÷ today's market cap ($10.6B). Same caveat as the cash buyback yield.: 0.71%2019-06 0.0%2026-09 0.7%

Vs own 10Y history

P/E: 31st
P/OI: 63rd
P/S: 28th
P/B: 20th
P/FCF: 73rd

Bar = where today’s multiple sits in AVTR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

+0.38%

-6.23%

+2.02%

+14.40%

YTD

+36.56%

+35.15%

-59.78%

+0.38%

-6.23%

+2.02%

+14.40%

YTD

+36.56%

+35.15%

-59.78%

Fundamentals#

Revenue

5Y CAGR +0.5%5Y CAGR +0.5%YoY +4.6%

$6.6B TTM$1.7B Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m

$487.2M TTM$139.5M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m

$0.50 TTM$0.30 Q3 '26

FY18FY19FY20FY21FY22FY23FY24FY25TTM

Free cash flow

5Y CAGR −10.6%5Y CAGR −10.6%YoY −9.0%

$439.2M TTM$156.2M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $584.7M, capex −$145.5M

Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $195.1M, capex −$38.9M

Shares (diluted)

5Y +16.7%5Y +16.7%YoY −0.1%

678.3M TTM680.9M Q3 '26

FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m

$337.2M TTM$203.4M Q3 '26

FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Full AVTR financials →

About Avantor#

Avantor, Inc. is a global life science tools and advanced technology company that supplies mission-critical products and services to customers in biopharma, healthcare, education and government, and applied materials industries. Its portfolio includes laboratory chemicals, reagents, consumables, equipment, instrumentation, single-use bioprocessing components, and specialty services that support research, development, production, and quality control. The company also provides customized materials and procurement solutions for highly regulated environments, helping laboratories and production teams maintain consistent workflows across the scientific supply chain. Avantor serves customers across the Americas, Europe, Asia, the Middle East, and Africa, with operations centered in Radnor, Pennsylvania.

Radnor, PA·13,500 employees·Medical Instruments & Supplies·avantorsciences.com·As of Oct 30, 2026

Recent filings#

Oct 28Earnings · Earnings release — EPS $0.22 vs $0.21 est. (+4.8%); revenue $1.70B (+5% y/y) 2.6%
Sep 218-K · Avantor appoints new Chief Financial Officer
Jul 29Earnings · Earnings release — EPS $0.21 vs $0.19 est. (+10.5%); revenue $1.69B (+1% y/y) 15.8%

All filings and insider trades →

ETFs holding AVTR#

19 of the 193 ETFs ChartRow carries live hold AVTR. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

Fund	Name	Filed weight
IJH	iShares Core S&P Mid-Cap ETF	0.2%
MDY	SPDR S&P MidCap 400 ETF Trust	0.2%
VBR	Vanguard Small-Cap Value ETF	0.1%
VHT	Vanguard Health Care ETF	0.1%
VB	Vanguard Small-Cap ETF	0.1%
VXF	Vanguard Extended Market ETF	0.1%
IWS	iShares Russell Mid-Cap Value ETF	0.1%
IWR	iShares Russell Midcap ETF	0.0%

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+24.07%	+0.61%
JNJ	Johnson & Johnson	+7.92%	+3.81%
ABBV	AbbVie Inc.	+12.18%	+3.09%
MRK	Merck & Co. Inc.	+4.20%	+3.93%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+10.08%	+1.22%
NVS	Novartis AG	+17.01%	+3.59%
TMO	Thermo Fisher Scientific Inc.	+7.84%	+1.12%
AMGN	Amgen Inc.	+18.69%	+3.71%

Head-to-head:Compare with BAX or any ticker →

AVTR — Avantor Inc. price, chart and key statistics

Key stats#

Price data

Volume

Insider trading

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price returntotal return · as of 2026-11-04#

Fundamentals#

Revenue

Operating income

EPS (diluted)

Free cash flow

Shares (diluted)

Net income

About Avantor#

Recent filings#

ETFs holding AVTR#

Related Healthcare#